4 December 2024 - ILiAD Biotechnologies today announced that the UK MHRA has granted Innovation Passport designation to BPZE1, the leading next generation intranasal pertussis vaccine. 

This innovative medicine designation has been awarded to BPZE1 indicated for active immunisation against both upper respiratory tract B. pertussis colonisation and symptomatic disease, more commonly known as whooping cough.

Read ILiAD Biotechnologies press release